Ken Griffin Ptc Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 16,900 shares of PTCT stock, worth $891,644. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,900

Previous 14,800 14.19%

Holding current value

$891,644

Previous $549,000 38.8%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$34.99 - $52.07 $7.66 Million - $11.4 Million	218,886 Added 91.53%	458,015 $20.7 Million
Q3 2024 Nov 14, 2024	SELL	$30.39 - $37.66 $940,570 - $1.17 Million	-30,950 Reduced 11.46%	239,129 $8.87 Million
Q2 2024 Aug 14, 2024	BUY	$24.69 - $40.12 $5.97 Million - $9.7 Million	241,741 Added 853.06%	270,079 $8.26 Million
Q1 2024 May 15, 2024	SELL	$24.15 - $31.95 $6.34 Million - $8.39 Million	-262,580 Reduced 90.26%	28,338 $824,000
Q4 2023 Feb 14, 2024	BUY	$18.07 - $29.37 $2.99 Million - $4.86 Million	165,512 Added 131.98%	290,918 $8.02 Million
Q3 2023 Nov 14, 2023	BUY	$22.41 - $41.99 $1.15 Million - $2.15 Million	51,098 Added 68.77%	125,406 $2.81 Million
Q2 2023 Aug 14, 2023	BUY	$40.4 - $59.1 $3 Million - $4.39 Million	74,308 New	74,308 $3.02 Million
Q4 2022 Feb 14, 2023	SELL	$33.53 - $54.79 $12.8 Million - $20.9 Million	-381,590 Reduced 99.64%	1,395 $53,000
Q3 2022 Nov 14, 2022	BUY	$41.85 - $53.85 $12.8 Million - $16.5 Million	306,990 Added 403.96%	382,985 $19.2 Million
Q2 2022 Aug 15, 2022	SELL	$25.6 - $45.23 $468,787 - $828,251	-18,312 Reduced 19.42%	75,995 $3.04 Million
Q1 2022 May 16, 2022	BUY	$33.33 - $44.6 $2.58 Million - $3.46 Million	77,506 Added 461.32%	94,307 $3.52 Million
Q4 2021 Feb 14, 2022	BUY	$35.36 - $41.86 $367,355 - $434,883	10,389 Added 162.02%	16,801 $669,000
Q3 2021 Nov 15, 2021	SELL	$37.01 - $44.74 $707,298 - $855,026	-19,111 Reduced 74.88%	6,412 $239,000
Q2 2021 Aug 16, 2021	SELL	$37.95 - $49.37 $2.1 Million - $2.74 Million	-55,453 Reduced 68.48%	25,523 $1.08 Million
Q1 2021 May 17, 2021	BUY	$46.8 - $68.92 $2.24 Million - $3.29 Million	47,766 Added 143.83%	80,976 $3.83 Million
Q4 2020 Feb 16, 2021	BUY	$47.96 - $67.64 $865,725 - $1.22 Million	18,051 Added 119.08%	33,210 $2.03 Million
Q3 2020 Nov 16, 2020	SELL	$45.41 - $57.07 $900,162 - $1.13 Million	-19,823 Reduced 56.67%	15,159 $709,000
Q2 2020 Aug 14, 2020	SELL	$42.56 - $54.98 $2.11 Million - $2.72 Million	-49,476 Reduced 58.58%	34,982 $1.78 Million
Q1 2020 May 15, 2020	SELL	$32.37 - $59.36 $42.6 Million - $78 Million	-1,314,660 Reduced 93.96%	84,458 $3.77 Million
Q4 2019 Feb 14, 2020	SELL	$32.22 - $50.07 $24.9 Million - $38.7 Million	-772,498 Reduced 35.57%	1,399,118 $67.2 Million
Q3 2019 Nov 14, 2019	BUY	$33.82 - $48.17 $12.9 Million - $18.4 Million	382,672 Added 21.39%	2,171,616 $73.4 Million
Q2 2019 Aug 14, 2019	SELL	$35.42 - $45.0 $10.7 Million - $13.6 Million	-303,251 Reduced 14.49%	1,788,944 $80.5 Million
Q1 2019 May 15, 2019	BUY	$28.09 - $39.49 $8.77 Million - $12.3 Million	312,142 Added 17.54%	2,092,195 $0
Q4 2018 Feb 14, 2019	BUY	$29.83 - $46.51 $39.3 Million - $61.3 Million	1,317,478 Added 284.81%	1,780,053 $61.1 Million
Q3 2018 Nov 13, 2018	BUY	$33.9 - $47.77 $9.7 Million - $13.7 Million	286,164 Added 162.21%	462,575 $0
Q2 2018 Aug 10, 2018	BUY	$25.7 - $47.88 $3.86 Million - $7.2 Million	150,387 Added 577.88%	176,411 $0
Q1 2018 May 11, 2018	SELL	$17.46 - $32.59 $2.51 Million - $4.69 Million	-144,007 Reduced 84.69%	26,024 $704,000
Q4 2017 Feb 09, 2018	BUY	$15.14 - $20.89 $2.57 Million - $3.55 Million	170,031	170,031 $2.84 Million

Others Institutions Holding PTCT

# of Institutions

258

Shares Held

77.4M

Call Options Held

179K

Put Options Held

536K

View Full List

About PTC THERAPEUTICS, INC.

Ticker PTCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,541,000
Market Cap $3.77B
Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...

More about PTCT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account